J Biol Chem, Vol. 274, Issue 41, 29122-29129, October 8, 1999
Membrane Topology of the Amino-terminal Region of the
Sulfonylurea Receptor*
Kimberly F.
Raab-Graham,
Laura J.
Cirilo,
Anne A.
Boettcher
,
Carolyn M.
Radeke, and
Carol A.
Vandenberg§
From the Department of Molecular, Cellular, and Developmental
Biology and the Neuroscience Research Institute, University of
California, Santa Barbara, California 93106
 |
ABSTRACT |
The sulfonylurea receptor (SUR) is a member of
the ATP-binding cassette family that is associated with Kir 6.x to form
ATP-sensitive potassium channels. SUR is involved in nucleotide
regulation of the channel and is the site of pharmacological
interaction with sulfonylurea drugs and potassium channel openers. SUR
contains three hydrophobic domains, TM0,
TM1, and TM2, with nucleotide binding folds
following TM1 and TM2. Two topological models
of SUR have been proposed containing either 13 transmembrane segments (in a 4+5+4 arrangement) or 17 transmembrane segments (in a 5+6+6 arrangement) (Aguilar-Bryan, L., Nichols, C. G., Wechsler, S. W., Clement, J. P. t., Boyd, A. E., III, González, G.,
Herrera-Sosa, H., Nguy, K., Bryan, J., and Nelson, D. A. (1995)
Science 268, 423-426; Tusnády, G. E., Bakos,
E., Váradi, A., and Sarkadi, B. (1997) FEBS Lett.
402, 1-3; Aguilar-Bryan, L., Clement, J. P., IV,
González, G., Kunjilwar, K., Babenko, A., and Bryan, J. (1998) Physiol. Rev. 78, 227-245). We analyzed the
topology of the amino-terminal TM0 region of SUR1 using
glycosylation and protease protection studies. Deglycosylation using
peptide-N-glycosidase F and site-directed mutagenesis
established that Asn10, near the amino terminus, and
Asn1050 are the only sites of N-linked
glycosylation, thus placing these sites on the extracellular side of
the membrane. To study in detail the topology of SUR1, we constructed
and expressed in vitro fusion proteins containing 1-5
hydrophobic segments of the TM0 region fused to the
reporter prolactin. The fusion proteins were subjected to a protease
protection assay that reported the accessibility of the prolactin
epitope. Our results indicate that the TM0 region is
comprised of 5 transmembrane segments. These data support the 5+6+6
model of SUR1 topology.
 |
INTRODUCTION |
ATP-sensitive potassium channels (KATP
channels)1 coordinate the
metabolic state of the cell with the electrical activity of the
membrane. KATP channels are weak inward rectifiers that are modulated by intracellular ATP/ADP ratios. The open state of the channel stabilizes the resting potential of the cell membrane near the
potassium equilibrium potential. Inhibition of KATP
channels by high levels of intracellular ATP or pharmacological
reagents such as sulfonylureas leads to membrane depolarization, which in turn induces insulin secretion from pancreatic
-cells and contraction in vascular smooth muscle. These channels have been implicated in the etiology or treatment of several pathophysiological disorders including persistent hyperinsulinemic hypoglycemia of infancy, ischemia, and hypertension (for review, see Refs. 1-3).
KATP is a heteromultimeric channel consisting of
pore-forming subunits Kir 6.x, which are members of the inwardly
rectifying potassium channel family, and regulatory subunits, the
sulfonylurea receptors (SUR), which are members of the ATP-binding
cassette (ABC) family. The Kir 6.x subunit dictates permeation and
rectification properties of the channel (2) and may contain the site
for ATP inhibition (4, 5). SUR subunits are involved in channel regulation by Mg2+-nucleotides, inhibition of channel
activity by sulfonylurea drugs used in the treatment of diabetes,
activation of the channel by potassium channel openers used in the
treatment of hypertension and persistent hyperinsulinemic hypoglycemia
of infancy, and trafficking of the channel to the plasma membrane
(6-12).
In light of the genetic and pharmacological importance of the SUR
subunit, understanding the topological organization of the protein will
assist in crucial structure-function and drug binding studies. Based on
sequence analysis, SUR is a multispanning transmembrane protein. It has
three hydrophobic domains, TM0, TM1, and
TM2, each of which is followed by a hydrophilic region
(Fig. 1A) (13). Within the
TM0, TM1, and TM2 domains are
multiple hydrophobic segments, each of which could potentially span the
membrane. Initial biochemical purification and amino-terminal
microsequencing of SUR1 indicated a glycosylation site near the amino
terminus (14, 15). Moreover, recent studies of the cloned receptor
suggest that the glycosylated form of the SUR1 protein is physically
associated with Kir 6.2 (16), suggesting an extracellular localization for the amino terminus of the SUR1 subunit in the KATP
channel. The two nucleotide binding folds (NBFs) are found within the
two hydrophilic domains following TM1 and TM2
(Fig. 1A). Mutational analysis and binding studies have
determined that both NBFs are sensitive to changes in intracellular
concentrations of Mg2+-ADP and Mg2+-ATP (8,
17-19). These data therefore suggest that the two NBFs are on the
cytoplasmic face of the membrane; however, the topology of the rest of
the protein has yet to be determined directly.

View larger version (36K):
[in this window]
[in a new window]
|
Fig. 1.
Hydrophobicity plot of SUR1 and proposed
models. Panel A, hydrophobicity plot of hamster SUR1
was constructed with a window size of 11 amino acids (24). Hydrophobic
domains (TM0, TM1, and TM2) and
nucleotide binding folds (NBF1 and NBF2) are
indicated above. Panel B, Tusnády et al.
(13) model of SUR1 suggests a total of 17 transmembrane segments with a
5+6+6 arrangement. Panel C, Aguilar-Bryan et al.
(14) model of SUR1 suggests a total of 13 transmembrane segments with a
4+5+4 arrangement.
|
|
To date, two topological models have been proposed in the literature
based on hydrophobicity analysis and sequence alignment with other ABC
proteins (Fig. 1, B and C). Tusnády
et al. proposed a total of 17 transmembrane segments grouped
within the three hydrophobic modules TM0, TM1,
and TM2 with a 5+6+6 arrangement, respectively (Fig.
1B) (2, 13). An alternative model suggested 13 transmembrane
segments (4+5+4) (Fig. 1C) (14). Tusnády et al. (13) proposed that all ABC proteins possess the "core"
TM1 and TM2 modules typified by the cystic
fibrosis transmembrane regulator and P-glycoprotein. A subset of the
ABC proteins, however, has an additional hydrophobic amino-terminal
TM0 domain. This subset includes SUR, multidrug
resistance-associated protein (MRP), MRP-related liver canalicular
multispecific organic anion transporter, rabbit epithelial basolateral
chloride conductance regulator, and yeast cadmium factor 1. It has been
suggested that the topological organization of the ABC proteins may
reveal common functional domains within the superfamily. Recently, it
has been speculated that the unique TM0 region might
influence drug binding affinities and/or transport properties because
all of these proteins bind or transport drugs (13, 20).
We report here the membrane topology of the TM0 domain of
SUR1. We chose to investigate the TM0 domain for several
reasons. First, the membrane topology of the amino-terminal region
often influences the folding of the rest of the protein (21-23).
Second, this domain is unique compared with that of most ABC proteins; and finally, the models proposed in the literature describing the
topology of SUR differ in the number of hydrophobic regions specified
in this domain (Fig. 1, B and C) (2, 13, 14). Our
findings suggest that the TM0 region of SUR1 associated
with Kir 6.2 consists of five transmembrane segments with the amino terminus localized to the extracellular side of the membrane and the
hydrophilic region between TM0 and TM1 on the
cytoplasmic side of the membrane.
 |
EXPERIMENTAL PROCEDURES |
Computer Analysis--
The locations of membrane-spanning
helicies in hamster SUR1 were predicted using hydrophobicity analysis
(24), hidden Markov methods HMMTOP (25) and TMHMM (26), the SOSUI
algorithm (27), the neural network PredictProtein (28), and the
TopPred2 method (29).
Plasmid Constructions--
Hamster SUR1 cDNA (14) was
subcloned into pcDNA3.1/HisC (Invitrogen) at the EcoRI
site to create full-length SUR1 with an amino-terminal His tag.
Full-length SUR1 with a carboxyl-terminal V5-fusion tag was created by
replacement of the stop codon with an XhoI site and
subcloning into the EcoRI-XhoI sites of
pcDNA3.1/V5-HisA (Invitrogen).
Construction of SUR-Prolactin Fusion Proteins--
cDNAs
coding for the amino-terminal region of SUR1 were fused to the soluble
portion of bovine prolactin, resulting in SUR74PL, SUR102PL, SUR134PL,
SUR168PL, SUR202PL, SUR248PL, and SUR285PL. Each fusion protein
contained the amino terminus of SUR1 through the amino acid number
indicated followed by a 1-amino acid Gly linker, then the
carboxyl-terminal 142 amino acids of bovine prolactin, omitting the
prolactin signal sequence. First, a cDNA (SUR296-pcDNA) coding
for the first five hydrophobic segments of SUR1 was made by truncating
SUR1 after amino acid 296 via digestion of SUR1-pcDNA3.1/HisC with
BsmBI, treating with Klenow then with EcoRV, and
ligating. SacII sites were introduced individually directly
following the nucleotides encoding Arg74,
Arg102, Arg134, Lys168,
Arg202, Arg248, and Arg285 in
SUR296-pcDNA, and just before Cys58 of bovine prolactin
by site-directed mutagenesis (CLONTECH). The amino
acid sequence at the fusion site was preserved with the exception of a
Lys168 to Arg168 change in the SUR168PL
construct. The cDNA encoding the carboxyl-terminal 142 amino acids
of bovine prolactin was fused to SUR1 at the inserted SacII
site and the vector XbaI site. All constructs were sequenced over the region of fusion (Sequenase 2.0, Amersham Pharmacia Biotech). Constructs lacking the amino-terminal His tag were then subcloned into
the high expression vector pGEMHE at the EcoRI and
XbaI sites. Thus, two sets of SUR-prolactin fusion proteins
were generated: SURxxxPL and His-SURxxxPL, with the latter group
containing an amino-terminal His tag.
Deletion of Glycosylation Sites--
Candidate
N-linked glycosylation sites at Asn10 and/or
Asn1050 were mutated to create proteins lacking one
(SUR-N10Q and SUR-N1050Q) or both (SUR-N10Q,N1050Q) putative
glycosylation sites.
Cloning of Kir 6.2--
Rat Kir 6.2 was cloned by polymerase
chain reaction from a rat heart cDNA
library2 using primers for
the nucleotide sequences 52-70 and 1463-1479 of mouse Kir 6.2 cDNA (6). The polymerase chain reaction product ends were blunted,
ligated into the SmaI site of Bluescript KS
(Stratagene),
sequenced on both strands, then subcloned into the BamHI-EcoRI sites of pcDNA1/Amp (Invitrogen).
Expression of SUR1 and Kir 6.2 in COS-1 Cells--
COS-1 cells
were cultured in Dulbecco's modified Eagle's medium with 10% fetal
calf serum. SUR1, SUR-N10Q, SUR-N1050Q, and SUR-N10Q,N1050Q (20-30
µg/100-mm plate) were cotransfected with Kir 6.2 (1-4 µg/100-mm
plate) using pFx-2 (Invitrogen). 48 h after transfection, COS-1
cells were rinsed twice with phosphate-buffered saline and lifted with
5 mM EDTA, 5 mM EGTA in phosphate-buffered saline. Cells were pelleted, homogenized in buffer A (0.25 M sucrose, 20 mM Hepes, pH 7.4, 5 mM TCEP, 1 mM EDTA, 15 µg/ml DNase, 10 µg/ml RNase, 1 × CompleteTM protease inhibitor
mixture (Roche Molecular Biochemicals)), and the nuclear fraction was
pelleted at 80 × g for 10 min. The supernatant was
saved, and the pellet was rehomogenized in buffer A and centrifuged as
above. Supernatants were combined, and membranes were centrifuged at
100,000 × g for 30 min at 4 °C and then resuspended
in buffer A and stored at
80 °C.
Enzymatic Deglycosylation--
Membrane protein (5-20 µg)
from COS-1 cells transfected with Kir 6.2 and SUR1 or in
vitro translated SUR-prolactin fusion proteins (10 µl, see
methods below) were treated with the glycosidase PNGase F. In brief,
protein was denatured by boiling for 10 min in 0.5% SDS, 1%
-mercaptoethanol. Sodium phosphate, pH 7.5, and Nonidet P-40 were
added to a final concentration of 50 mM and 1%,
respectively. Samples were incubated with 5 units (for membrane protein) or 2.5 units (for fusion protein) of PNGase F (New England Biolabs) at 37 °C for 1 h. Products were analyzed by SDS-PAGE followed by autoradiography or Western blot.
Immunoblot Analysis of SUR1--
Samples containing 5-20 µg
of total membrane protein isolated from COS-1 cells cotransfected with
Kir 6.2 and SUR1 were solubilized in TCEP-SDS sample buffer (15 mM Tris, pH 9.0, 2.5% glycerol, 2% SDS, 0.1 mM EDTA, 2 mM TCEP) and boiled for 20 min.
After separation by SDS-PAGE (2-12% gradient), proteins were
transferred to nitrocellulose (Hybond, Amersham Pharmacia Biotech),
analyzed by immunoblotting with V5 antibody conjugated to horseradish
peroxidase (1:1,000; Invitrogen), and visualized by chemiluminescence
(Super SignalTMWest Dura; Pierce).
Protease Protection Assay of Fusion Proteins--
SUR-prolactin
fusion proteins were translated in vitro using a coupled
transcription/translation system in the presence of [35S]Met and canine pancreatic microsomal membranes (4 equivalents/25 µl, Promega). 10-µl samples of in vitro
translated fusion protein were treated with 10 µg/ml proteinase K
(Stratagene) in the presence and absence of 1.2% Trition X-100 for
1 h on ice. The reaction was quenched by the addition of 25 mM phenylmethylsulfonyl fluoride. Microsomes were pelleted
at 16,000 × g for 20 min at 4 °C. The supernatant
was removed, and the membranes were resuspended in 1% SDS, 50 mM Tris, pH 8.0. Samples were incubated at 100 °C for 10 min, diluted to a final concentration of 0.1% SDS with buffer B (1%
Nonidet P-40, 20 mM Hepes, pH 7.0, 150 mM NaCl,
5 mM EDTA, and 1 mM phenylmethylsulfonyl
fluoride), and immunoprecipitated with anti-prolactin antibody.
Positive control fusion protein samples were subjected to the same
protocol omitting the proteinase K and Triton X-100 treatment. To
assess the integrity of the microsomes, a parallel sample containing
in vitro translated bovine prolactin was similarly subjected
to proteinase K treatment as an additional control that was included in
each experiment.
Immunoprecipitation of Products--
The prolactin reporter, ± proteinase K treatment, was immunoprecipitated, separated by SDS-PAGE,
and detected by autoradiography. In brief, polyclonal rabbit anti-sheep
prolactin antibody (ICN) was preabsorbed to protein A or G agarose
beads (Pierce) at room temperature for 2 h. The antibody-protein
A/G complex was washed once in buffer B, mixed with solubilized protein
for a final antibody dilution of 1:500, and incubated at room
temperature for 1-2 h with constant agitation. The
protein-antibody-protein A/G complex was washed twice with buffer B
followed by a final wash with H2O. Protein was eluted by
boiling in SDS sample buffer for 5 min and then analyzed by SDS-PAGE on
a reducing 13.5 or 15% gel followed by autoradiography.
 |
RESULTS |
Predicted Topologies of SUR1--
Analysis of the amino acid
sequence of SUR1 using algorithms that identify putative transmembrane
helices predicted several topologies for SUR1. The various algorithms
that were tested (25-29), together with the models in the literature
(13, 14), produced a total of six models containing 13, 15, 16, 17, or
18 transmembrane helices, with none of the models identical. Of the
three algorithms designed to predict helix orientation, all suggested
that the amino terminus resided extracellularly. These predictions are consistent with the significant positive charge difference
(C-N) of
residues surrounding the first hydrophobic segment of SUR1 which typify
an extracellular amino terminus (23).
Many transmembrane helices were predicted consistently, whereas others
were identified only by some of the algorithms. In the TM0
region, between four and six transmembrane segments were predicted. The
Tusnády et al. model suggested five transmembrane segments in this area (13). The third of these (HR3) was skipped in
some models, and in one case an additional transmembrane segment was
added following HR5. In contrast to the Tusnády et al.
model, which predicted an intracellular orientation for the large
hydrophilic loop between TM0 and TM1, the
models with four and six transmembrane segments in the TM0
region predicted an extracellular location for this loop.
The TM1 region was predicted to have five to eight
transmembrane segments (six in the Tusnády et al.
model (13)), with HR8 most frequently skipped. The TM2
region was predicted to have four to six transmembrane segments (six in
the Tusnády et al. model (13)), with HR14 and HR17
most frequently skipped. Only three of the six models predicted an even
number of transmembrane segments in the TM2 region, which
resulted in placement of the nucleotide binding folds on the same side
of the membrane for only half of the models. Overall, the topology
predictions showed that although several features of the SUR1 topology
can be predicted, there was no agreement on the transmembrane
assignments or orientations by the modeling algorithms.
Analysis of Endogenous Glycosylation Sites--
To begin our study
of the topology of SUR1 we investigated the endogenous sites of
N-linked glycosylation. Purification and microsequencing of
the sulfonylurea receptor had suggested previously that the amino
terminus of SUR1 is glycosylated, indicating an extracellular location
(14, 15). To explore this possibility further we examined the
glycosylation state of the consensus glycosylation acceptor sites
(Asn-Xaa-Ser/Thr) at Asn10 and Asn1050 in SUR1.
In both topological models presented in the literature these two sites
are predicted to reside on the extracellular side of the membrane (Fig.
1, B and C). Immunoblot analysis of SUR1 using an
epitope-specific V5 antibody detected the presence of two major bands
of approximately equal intensities at apparent molecular masses of 187 and 164 kDa when SUR1 was coexpressed with Kir 6.2 (Fig.
2, first lane), consistent
with previous reports of mature "complex" glycosylation and
immature "core" glycosylation forms of SUR (15). Upon treatment of
SUR1 with the endoglycosidase PNGase F, which is specific for
N-linked glycosylation, SUR1 migrated as a single band (Fig.
2, second lane) at a relative mobility similar to the lower
band in the untreated sample. The mobility of immature SUR1 was not
easily differentiated from that of unglycosylated SUR1 in Fig. 2
(first two lanes) because of the minor difference of ~3
kDa in molecular mass between the two forms (15). When SUR1 was
expressed in the absence of Kir 6.2, the resulting band comigrated with
the immature form of the protein (data not shown), consistent with
reports that the highly glycosylated form of SUR1 is found when Kir 6.2 is coexpressed (16).

View larger version (40K):
[in this window]
[in a new window]
|
Fig. 2.
Glycosylation of full-length SUR1 indicates
that Asn10 and Asn1050 are extracellular.
Full-length SUR1, SUR-N10Q, SUR-N1050Q, and SUR-N10Q,N1050Q were
coexpressed with Kir 6.2 in COS-1 cells and identified by
immunoblotting with an antibody to a carboxyl-terminal V5 epitope tag.
Asn10 and/or Asn1050 of SUR1 was mutated to Gln
to remove the N-glycosylation acceptor site. The samples
were treated with and without PNGase F to remove the
N-linked carbohydrate. The arrow indicates the
mobility of the immature and unglycosylated forms of the protein; the
asterisk indicates the mature glycosylated protein.
|
|
To determine which residues were glycosylated, the predicted
glycosylation acceptor sites Asn10 and Asn1050
were mutated either individually (SUR-N10Q, and SUR-N1050Q) or together
(SUR-N10Q,1050Q). Expression of SUR-N10Q (Fig. 2, third and
fourth lanes) and SUR-N1050Q (Fig. 2, fifth and
sixth lanes) demonstrated that elimination of either of the
Asn10 or Asn1050 glycosylation consensus sites
resulted in a significant decrease of mature glycosylated receptor
compared with wild type SUR1. Furthermore, simultaneous removal of both
the Asn10 and Asn1050 sites in SUR-N10Q,N1050Q
resulted only in a band that comigrated with the unglycosylated form of
the protein (Fig. 2, seventh and eighth lanes),
indicating that both Asn10 and Asn1050 were
glycosylated in wild type SUR1. A reduction in glycosylation on
SUR-N10Q relative to wild type SUR1 is in agreement with previous studies suggesting that Asn10 on the SUR1 amino terminus is
glycosylated (14, 15). These results place both the amino terminus and
the hydrophilic region containing amino acid 1050 on the extracellular
side of the membrane. Asn1050 is located in the
TM2 domain and is predicted to reside extracellularly between the 12th and 13th putative transmembrane segments in the 5+6+6
model of Tusnády et al. (13).
Hydrophobicity Analysis and Construction of the Fusion
Proteins--
We chose a classical protease protection approach to
investigate which HRs span the membrane. Seven chimeric cDNAs were
constructed which code for the amino terminus of SUR1 fused to the
prolactin reporter. The prolactin reporter, consisting of the
carboxyl-terminal soluble portion of prolactin, has been shown to have
no effect on upstream signal and stop transfer sequences (30, 31). The constructs were based on the calculated hydrophobicity plot
encompassing the TM0 domain of hamster SUR1 (Fig.
3A) (24). This plot identified five HRs ranging from 18 to 22 amino acids which could potentially span
the membrane. Prolactin was fused after each putative membrane-spanning region at the carboxyl-terminal end of the downstream hydrophilic loop
(Fig. 3B). The location of each fusion site was chosen to preserve the charged residues surrounding the transmembrane segments because it has been suggested that charged regions flanking
transmembrane segments may influence the orientation of the
membrane-spanning region and thus, the native topology of the protein
(32). Three of the constructs (SUR202PL, SUR248PL, and SUR285PL)
contain increasing lengths of the hydrophilic linker following HR5 to
ensure that this entire region resides on the same side of the
membrane.

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 3.
Hydrophobicity plot of TM0 region
of SUR1 and schematic diagram of chimeric constructs. Panel
A, a hydrophobicity plot of the TM0 region of SUR1 was
constructed with a window size of 11 amino acids (24).
Asterisks indicate the location of transmembrane segments
proposed in two models (gray, Aguilar-Bryan et
al. (14); black, Tusnády et al. (13)).
Amino acids included in the five hydrophobic regions are as follows:
HR1, 30-51; HR2, 75-94; HR3, 106-124; HR4, 135-155; and HR5,
169-190. Panel B, SUR-prolactin fusion proteins. The
prolactin epitope was fused to SUR1 following each of the predicted
hydrophobic regions. Three fusion proteins were engineered following
the hydrophilic tail after HR5.
|
|
Glycosylation State of SUR-Prolactin Fusion Proteins--
To
ensure that the topological orientation of the amino terminus of the
SUR-prolactin fusion proteins was consistent with that of full-length
SUR1 expressed in cells, we analyzed the glycosylation state of
Asn10 in the SUR285PL fusion protein. In vitro
translation of SUR285PL in the presence of microsomes resulted in two
major bands corresponding approximately to the molecular mass expected
of the full-length fusion protein (Fig.
4, first lane): an upper band
of apparent molecular mass of ~40 kDa and a lower band of ~37 kDa.
An additional band below the full-length fusion protein is probably a
truncated product of the protein, as commonly seen with in
vitro translation (33).

View larger version (77K):
[in this window]
[in a new window]
|
Fig. 4.
Glycosylation of SUR285PL and SUR285PL-N10Q
fusion proteins. Autoradiograms are shown of SUR285PL and
SUR285PL-N10Q fusion proteins that were translated in vitro
in the presence of [35S]Met and canine pancreatic
microsomes. Asn10 in SUR285PL-N10Q was mutated to remove
the N-glycosylation acceptor site. The samples were treated
with and without PNGase F to remove the N-linked
carbohydrate and resolved on an 8.75% SDS-polyacrylamide gel. The
arrow indicates the unglycosylated form of the protein; the
asterisk indicates the glycosylated protein.
|
|
Upon treatment with the glycosidase PNGase F, the 40-kDa band was
reduced to the same relative mobility as the 37-kDa band (Fig. 4,
second lane), demonstrating that the difference in molecular mass is caused by N-linked glycosylation. In
vitro translation in the presence of microsomes results in
proteins that are core glycosylated, but not mature glycosylated,
indicating that the 40- and 37-kDa bands represent the immature core
glycosylated and unglycosylated forms of the protein. These results are
in agreement with previous reports that the immature form of SUR is
approximately 3 kDa greater in mass than the unglycosylated receptor
(15). The primary sequence of SUR285PL predicts only one consensus
sequence for N-linked glycosylation at Asn10.
Mutation of that site in SUR285PL-N10Q produced a single band at the
same apparent molecular mass as the unglycosylated SUR285PL protein,
and its mobility was not shifted by PNGase F treatment (Fig. 4,
third and fourth lanes), showing that
Asn10 is glycosylated in the SUR285PL fusion protein. The
relative amounts of the glycosylated and the unglycosylated fusion
protein varied, but typically they were approximately equal. Because
the glycosylated protein must be oriented with the amino-terminal extracellularly, this suggests that at minimum, half of the protein is
translated in this orientation. It is likely that much of the unglycosylated protein also assumes the same orientation because glycosylation is known to be incomplete in this assay (33).
The TM0 Domain of SUR1 Can Assume Two Topologies in
Microsomal Membranes with Opposite Transmembrane Orientations of the
Protein--
To examine the transmembrane topology of the
TM0 domain, fusion proteins were translated in the presence
of microsomes and [35S]Met, treated with the proteolytic
enzyme proteinase K, and immunoprecipitated with a prolactin-specific
antibody. If the prolactin reporter were fused to an amino acid that
places it within the microsome, a position destined to become
extracellular, then prolactin would be protected from proteolytic
digestion, and a radioactive band should be detected by
autoradiography; however, if the prolactin reporter is on the outside
of the microsome, in a cytoplasmic orientation, it should be digested
by the protease, and consequently no radioactive band should be
detected. Thus, constructs with an increasing number of hydrophobic
regions might be expected to alternate between protection and
degradation of the prolactin reporter each time the prolactin fusion
site crosses the membrane (30, 31, 34).
In contrast to our expectation of alternating prolactin protection and
accessibility, we observed two proteolysis patterns of SUR-prolactin
constructs. Both patterns retained prolactin protection from protease
digestion, but the sizes and proteolytic pattern of each group were
suggestive of two populations of in vitro translated fusion
proteins: one with the amino terminus destined to be
extracellular (Nexo; intramicrosomal) and one with the
amino terminus intracellular (Ncyt; cytoplasmic), each with five transmembrane segments. To address each separately, we will describe first the constructs with an even number of SUR
hydrophobic regions (SUR102PL and SUR168PL), then those
with an odd number of hydrophobic regions (SUR74PL, SUR134PL,
SUR202PL, SUR248PL, and SUR285PL).
Protection of Prolactin Reporter in Fusion Proteins Consisting of
an Even Number of Hydrophobic Regions--
Fig.
5 illustrates the proteolytic pattern of
the fusion proteins comprised of two and four hydrophobic regions.
Schematic diagrams represent the two proposed topologies of the
corresponding fusion proteins in the assay. The top diagram
shows the protected prolactin reporter (intramicrosomal), consistent
with the fusion protein in the Nexo orientation. The
bottom diagram illustrates the digested prolactin reporter
(extramicrosomal) which suggests the alternate, Ncyt
orientation of the fusion protein.

View larger version (45K):
[in this window]
[in a new window]
|
Fig. 5.
Immunoprecipitation of the protected
prolactin reporter in fusion proteins with an even number of
hydrophobic regions. SUR102PL (panel A) and SUR168PL
(panel B) chimeric cDNAs coding for two and four
hydrophobic regions were translated in vitro in the presence
of [35S]Met and canine pancreatic microsomes. Fusion
protein was left untreated ( ) or treated (+) with proteinase K in the
absence ( ) or the presence (+) of Triton X-100, followed by
immunoprecipitation with anti-prolactin antibody, SDS-PAGE, and
autoradiography. The gray asterisk and arrow to
the right of each autoradiogram indicate the glycosylated
and the unglycosylated forms of the protein, respectively. The
black arrow indicates the protease-protected peptide. The
two topological orientations of the fusion protein are diagramed to the
right of the autoradiogram with intramicrosomal above and
extramicrosomal below the diagramed membrane. Arrows in the
diagrams indicate the proposed protease-sensitive sites. Glycosylation
is denoted by the tree-like structure on the amino terminus of the
protein. The broken line outlining the prolactin reporter
indicates digestion of the epitope by the protease. Panel A,
proteinase K treatment of SUR102PL fusion protein resulted in a
protected peptide with an apparent molecular mass of ~15 kDa
(black arrow), suggesting a protease-sensitive site between
HR1 and HR2 (black arrows in the top diagram,
panel A). One-quarter of the SUR102PL fusion protein ( )
protease (first lane) was loaded on the gel
relative to the fusion protein (+) protease (second and
third lanes) to visualize the glycosylated and
unglycosylated form of the protein. Panel B, proteinase K
treatment of SUR168PL fusion protein resulted in the protection of two
peptides with apparent molecular masses of 26 and 17 kDa (black
arrows). These peptides are consistent with the presence of two
protease-sensitive sites between HR1-2 and HR3-4 (black
arrows in the top diagram, panel B). The
SUR168PL fusion protein (+) protease autoradiogram was exposed eight
times longer than the sample ( ) protease.
|
|
To determine if an immunoprecipitated peptide was a protected fragment
of the SUR-prolactin fusion protein, we heeded the following criteria:
1) the peptide must be specifically immunoprecipitated with the
anti-prolactin antibody in a reproducible manner; 2) the peptide must
be protected from proteolysis in the absence of detergent and must be
degraded when proteolysis is performed after solubilization of the
microsomes; and 3) the peptide must not be present in the prolactin
control samples or the samples that were not treated with protease.
The fusion protein SUR102PL, which contains two hydrophobic regions,
shows a doublet corresponding to the glycosylated and unglycosylated
forms of the protein (Fig. 5A, first lane,
gray asterisk and arrow). In separate experiments
the upper band was shown to be glycosylated by its
sensitivity to PNGase F treatment (data not shown), as was seen with
all of the SUR-prolactin fusion proteins tested (e.g. Fig.
4). The unglycosylated protein had an apparent molecular mass of 27 kDa
with a predicted molecular mass of 28 kDa.
The SUR102PL fusion protein treated with proteinase K produced a
protease-protected peptide of an apparent molecular mass of 15 kDa
(n = 7; Fig. 5A, second lane,
black arrow). Upon treatment of the fusion protein with the
protease in the presence of detergent, the prolactin epitope was
completely degraded, eliminating the possibility that the protected
peptide represented a protease-insensitive fragment (Fig.
5A, third lane). A protected peptide
corresponding to a predicted molecular mass of ~20 kDa is consistent
with a protease-sensitive site between HR1 and HR2 as shown in the
Nexo orientation (top diagram). The resulting
protease-protected peptide of ~15 kDa is within a reasonable range to
correspond to HR2 fused to the protected prolactin epitope. An
alternative explanation, that the peptide is a proteolytic fragment of
the minor band observed below the unglycosylated fusion protein (Fig.
5A, first lane), was unlikely because in other
experiments the protected peptide was still present when the minor band
was absent.
When SUR168PL fusion protein, containing four hydrophobic regions, was
treated with proteinase K, two bands of apparent molecular masses of 26 and 16 kDa were immunoprecipitated with anti-prolactin, in addition to
a band with the same mobility as the glycosylated full-length construct
(n = 5; Fig. 5B). The peptide of 26 kDa is
in close agreement with the predicted molecular mass of 27 kDa if the
fusion protein were clipped at amino acid 74 between HR1 and HR2 (Fig.
5B, top diagram). These results are consistent with the protease-sensitive site observed for the SUR102PL construct (Fig. 5A). Similarly, the protected peptide with an apparent
molecular mass of 16 kDa is consistent with a protease-sensitive site
between HR3 and HR4 (predicted molecular mass of 20 kDa; Fig.
5B, top diagram). These data show that each of
the first four HRs of SUR1 forms a transmembrane segment, and they
further indicate that the protected prolactin reporter in fusion
proteins comprised of an even number of hydrophobic regions represents
a population of proteins that are in the Nexo orientation.
Protection of Prolactin Reporter in Fusion Proteins Consisting of
an Odd Number of Hydrophobic Regions--
Fig.
6 illustrates the protease protection
pattern of the fusion proteins consisting of an odd number of
hydrophobic regions. The schematic diagrams indicate that the prolactin
reporter in fusion proteins with an odd number of hydrophobic regions
will be digested in proteins having the Nexo orientation
(top diagram) but will be protected in a fraction of the
population if those proteins are translated in an Ncyt
orientation (bottom diagram). Thus, protease-protected
fragments will be present if some of the fusion protein is translated
in an Ncyt orientation.

View larger version (48K):
[in this window]
[in a new window]
|
Fig. 6.
Immunoprecipitation of the protected
prolactin reporter in fusion proteins with an odd number of hydrophobic
regions. Autoradiograms are shown for SUR74PL, SUR134PL, and
SUR202PL fusion proteins containing one (panel A), three
(panel B), and five (panel C) hydrophobic
regions. Fusion proteins with or without an amino-terminal His tag were
left untreated ( ) or digested (+) with proteinase K in the absence
( ) or the presence (+) of Triton X-100 and then immunoprecipitated
with anti-prolactin; the peptides were separated on a 13.5 or 15%
SDS-polyacrylamide gel. The gray asterisk and
arrow to the right of the autoradiogram indicate
the glycosylated and the unglycosylated form of the proteins,
respectively. The black arrow indicates the
protease-protected peptide. The diagrams to the right of the
autoradiogram depict the two proposed topological models of the
corresponding fusion protein, with the Nexo orientation
(top) and Ncyt orientation (bottom).
The arrows in the diagrams indicate protease-sensitive sites
in the corresponding fusion protein. One-quarter of the samples ( )
proteinase K were loaded on the gel relative to the samples (+)
protease, except for panel B (left), where equal
amounts of SUR134PL without the His tag were loaded.
|
|
Proteolysis of fusion proteins SUR74PL (HR1), SUR134PL (HR1-3), and
SUR202PL (HR1-5) resulted in protected peptides (Fig. 6) but with a
proteolytic pattern different from that observed previously for the
even numbered hydrophobic regions (Fig. 5). For each of the
SUR-prolactin constructs with an odd number of hydrophobic regions, a
band migrating with a slightly faster mobility than the unglycosylated
form of the protein was present after protease treatment (compare
first two lanes in Fig. 6, A-C). The molecular
mass of the protected peptide was ~2-5 kDa less than the apparent
molecular mass of the unglycosylated protein (SUR74PL, n = 4; SUR134PL, n = 5; SUR202PL,
n = 6). This difference in size is consistent with
degradation of the hydrophilic amino terminus of ~3 kDa (amino acids
1-29).
To determine whether the amino terminus was removed by proteinase K
treatment, the length of the amino terminus was increased by the
addition of a His tag (Fig. 6, A-C, fourth
through sixth lanes). In vitro translated
proteins with the His tag were not glycosylated; and because of the
addition of the tag, they migrated at an apparent molecular mass ~4
kDa more than the unglycosylated form of the protein without the His
tag (compare first and fourth lanes of Fig. 6,
A-C). Upon proteinase K treatment, each of the His-tagged
proteins produced a band migrating at a size ~5-10 kDa smaller than
the unproteolyzed fusion protein, showing that a larger amino terminus
had been removed. Furthermore, the size of the fragment after
proteolysis was the same whether it was derived from proteolysis of
fusion proteins with or without an amino-terminal His tag. These data
indicate that the amino terminus was degraded and therefore,
cytoplasmic (Fig. 6, A-C, bottom diagrams). Similar results were observed with fusion proteins SUR248PL and SUR285PL (containing HR1-5) with and without the amino-terminal His
tag (SUR248, n = 6; SUR285, n = 3; data
not shown). For the fusion proteins with an odd number of hydrophobic
regions, data are consistent with each of these regions being
transmembrane, in agreement with the results from constructs with an
even number of hydrophobic regions.
Based on the protease protection results, the TM0 region of
SUR1 contains five transmembrane segments. Glycosylation studies and
SUR-prolactin constructs with an even number of HRs suggest that the
amino terminus is extracellular; however, the SUR-prolactin fusion
proteins with an odd number of HRs indicate that some of the fusion
protein can assume a topology with the amino terminus cytoplasmic. We considered an alternative interpretation of the data:
that the protein was synthesized in one orientation but that some
percentage of the microsomes ruptured and recircularized in an
"inside-out" orientation during handling. To test this alternative, we cotranslated full-length prolactin with the SUR-prolactin fusion protein SUR248PL. Full-length prolactin was used as a control because
it is processed to a smaller soluble form that is trapped within the
microsome, thus permitting assessment of microsomal integrity. These
controls showed that processed prolactin was not accessible to
digestion by proteinase K, thus indicating that the microsomes remained
intact (data not shown). These data argue against microsomal
reorientation and suggest that the dual topology of TM0 in
the in vitro translated protein is a product of protein biogenesis.
 |
DISCUSSION |
The TM0 domain of SUR1, and the analogous region in
other MRP-related proteins, has been predicted to contain between four and six transmembrane segments (2, 13, 14). To date, the topology of
this region of SUR has only been investigated by interpretation of the
hydrophobicity profile and amino acid sequence, with the added
constraint of an extracellular amino terminus (14). In this study we
have used a combination of fusion protein constructs in a protease
protection assay and analysis of endogenous N-linked glycosylation sites to determine systematically the number of transmembrane segments that encompass the TM0 region of
SUR1. Herein we report the first experimental determination that the TM0 domain, common among MRP-related ABC proteins, consists
of five transmembrane segments.
Our analysis of wild type SUR1 and glycosylation mutants coexpressed
with Kir 6.2 in COS-1 cells demonstrated that the receptor is
glycosylated at two sites: Asn10 on the amino terminus and
Asn1050 located on the extracellular loop following the
first NBF. Both glycosylation sites are conserved among the MRP-related
ABC proteins (35, 36). In addition, other ABC proteins, such as the
cystic fibrosis transmembrane regulator, are glycosylated at a position equivalent to Asn1050 (37). These results therefore favor
the hypothesis that members of the ABC protein family may share common
transmembrane topologies.
Transmembrane Topology Mapping--
The method of
carboxyl-terminal truncation/fusion mapping has been used successfully
for mapping the topology of many multispanning transmembrane proteins
(31, 34, 38, 39). The two models proposed in the literature postulate
that the TM0 domain of SUR1 will consist of either four or
five transmembrane regions (Fig. 1). The hydrophobicity profile (Fig.
3) shows five hydrophobic peaks, ranging from 18 to 22 amino acids,
which are candidate regions for spanning the bilayer as an
helix,
with the HR3 segment being the least likely based on its shorter, less
hydrophobic sequence. We tested these hypotheses in a protease
protection assay. If the TM0 domain consists of four
transmembrane regions with the amino terminus extracellular (14, 15),
then the prolactin reporter would be protected when it was fused to
sites following HR2, HR3, or HR5 (SUR102PL, SUR134PL, SUR202PL,
SUR248PL, and SUR285PL). On the other hand, if the TM0
domain has five transmembrane regions with the amino terminus
extracellular (13), one would expect that the prolactin reporter fused
to sites following HR2 or HR4 (SUR134PL and SUR168PL) would be
protected. Our results agree with the latter prediction for a
five-transmembrane segment model of TM0, with the addition
that in the in vitro translation system, a fraction of the
chimeric proteins was oriented in the Ncyt direction.
Protease digestion of the even numbered HRs (SUR102PL and SUR168PL)
resulted in protected peptides consistent with the Tusnády
et al. model of five transmembrane segments (13).
Additionally, protease digestion of the odd numbered HRs (SUR74PL,
SUR134PL, SUR202PL, SUR248PL, and SUR285PL) resulted in protected
fragments indicating five transmembrane segments, yet with a
proteolyzed amino terminus suggesting a Ncyt orientation
for some of the protein. Taken together, our results suggest that all
five hydrophobic regions serve as transmembrane segments.
These results are consistent with the topology proposed for the
TM0 region of MRP, which is based on glycosylation near the MRP amino terminus, and localization of epitope tags inserted on each
side of HR5 (36, 40, 41). Those studies showed that in MRP, the fifth
hydrophobic segment of TM0 is a transmembrane segment and
that the hydrophilic loop between TM0 and TM1
is on the cytoplasmic side of the membrane (40).
Topological Model of SUR1 Associated with Kir 6.2--
Fig.
7 demonstrates our current view of the
topology of SUR1 associated with Kir 6.2 (13). The regions outlined in
black indicate the transmembrane orientation of regions
supported by experimental evidence, whereas the regions outlined in
gray have yet to be established. We favor this model because
it is the only topology that agrees with all of the following
experimental constraints: 1) the amino terminus, Asn10, is
glycosylated and therefore extracellular (reported above (14, 15)), as
is Asn1050; 2) Kir 6.2 is associated with the glycosylated
form of SUR1 (16), thus supporting the Nexo orientation
over the Ncyt orientation; 3) the TM0 domain
has five transmembrane segments as indicated by the protease protection
assay; 4) the NBFs reside on the cytoplasmic side of the membrane (8,
17-19); and 5) an epitope tag has indicated an extracellular
orientation between putative transmembrane segments 16 and 17 (12). At
this time, there is no evidence for more than one topology of SUR1 in
cells, but we cannot rule out the possibility that SUR1 expressed in
the absence of Kir 6.2 might assume an alternate topology, as alternate
topologies have been reported for several other membrane proteins (39,
42-45).

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 7.
Proposed topology of SUR1 associated with Kir
6.2. Protease protection and glycosylation (determined in this
report), together with nucleotide binding and physiological studies
have established the topological orientations of the SUR1 polypeptide
regions outlined in black. The tree-like structures indicate
the N-linked glycosylation sites at Asn10 and
Asn1050. Amino acid numbers designate the sites
at which the prolactin reporter was fused. In the Nexo
orientation, SUR102PL and SUR168PL were protected from the protease,
whereas SUR74PL, SUR134PL, SUR202PL, SUR248PL, and SUR285PL were
digested. NBF1 and NBF2 denote the two
nucleotide binding folds. The topology of the remainder of the protein
outlined in gray has not been determined.
|
|
Concluding Remarks--
These data suggest that the
TM0 domain of SUR1 consists of five transmembrane segments.
We have demonstrated that Asn10 is utilized as a
glycosylation acceptor site both in cells and in our in
vitro assay, suggesting that the amino terminus of SUR1 is on the
extracellular side of the membrane. Because Kir 6.2 has been shown to
associate with the glycosylated form of SUR1 to form the pancreatic
KATP channel, our data favor the model that SUR1 assumes a
5+6+6 topology (13). This model is in agreement with the topology
suggested for MRP from glycosylation and epitope insertion studies (35,
40, 41, 46). These results suggest that SUR1 and members of the
MRP-related subfamily of ABC proteins share a common membrane topology.
Recent work has demonstrated that the TM0 region of MRP is
necessary for the transport of the organic anion substrate leukotriene
C4 (20). Future work will determine the functional
significance of the TM0 domain in SUR1.
 |
ACKNOWLEDGEMENTS |
We thank Dr. Joseph Bryan and Dr. Lydia
Aguilar-Bryan for the SUR1 cDNA, Dr. William Hansen for the
prolactin cDNA, and Dr. Emily Liman for the pGEMHE vector. We also
thank Dr. Kathy Foltz for experimental advice and helpful discussion.
 |
FOOTNOTES |
*
This work was supported by National Institutes of Health
Grant HL41656 and California Tobacco-related Disease Research Program Grant 4RT-0289.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Present address: Dept. Biological Sciences, University of South
Alabama, Mobile, AL 36688.
§
To whom correspondence should be addressed. Tel.: 805-893-8505;
Fax: 805-893-2005; E-mail: vandenbe@lifesci.ucsb.edu.
2
F. Périer and C. A. Vandenberg,
unpublished data.
 |
ABBREVIATIONS |
The abbreviations used are:
KATP, ATP-sensitive potassium channel;
ABC, ATP-binding cassette;
HR, hydrophobic region;
Kir, inwardly rectifying potassium channel;
MRP, multidrug resistance-associated protein;
NBF, nucleotide-binding fold;
PL, prolactin;
SUR, sulfonylurea receptor;
Nexo, amino
terminus extracellular;
Ncyt, amino terminus cytoplasmic;
PAGE, polyacrylamide gel electrophoresis;
TCEP, tri(2-carboxyethyl)phosphine hydrochloride;
TM, transmembrane;
PNGase
F, peptide-N-glycosidase.
 |
REFERENCES |
| 1.
|
Ashcroft, F. M.
(1996)
Hormone Metab. Res.
28,
456-463[Medline]
[Order article via Infotrieve]
|
| 2.
|
Babenko, A. P.,
Aguilar-Bryan, L.,
and Bryan, J.
(1998)
Annu. Rev. Physiol.
60,
667-687[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Aguilar-Bryan, L.,
Clement, J. P., IV,
González, G.,
Kunjilwar, K.,
Babenko, A.,
and Bryan, J.
(1998)
Physiol. Rev.
78,
227-245[Abstract/Free Full Text]
|
| 4.
|
Tucker, S. J.,
Gribble, F. M.,
Proks, P.,
Trapp, S.,
Ryder, T. J.,
Haug, T.,
Reimann, F.,
and Ashcroft, F. M.
(1998)
EMBO J.
17,
3290-3296[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Koster, J. C.,
Sha, Q.,
Shyng, S. L.,
and Nichols, C. G.
(1999)
J. Physiol. (Lond.)
515,
19-30[Abstract/Free Full Text]
|
| 6.
|
Inagaki, N.,
Gonoi, T.,
Clement, J. P., IV,
Namba, N.,
Inazawa, J.,
González, G.,
Aguilar-Bryan, L.,
Seino, S.,
and Bryan, J.
(1995)
Science
270,
1166-1170[Abstract/Free Full Text]
|
| 7.
|
Sakura, H.,
Ammälä, C.,
Smith, P. A.,
Gribble, F. M.,
and Ashcroft, F. M.
(1995)
FEBS Lett.
377,
338-344[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Gribble, F. M.,
Tucker, S. J.,
and Ashcroft, F. M.
(1997)
EMBO J.
16,
1145-1152[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Gribble, F. M.,
Ashfield, R.,
Ammälä, C.,
and Ashcroft, F. M.
(1997)
J. Physiol. (Lond.)
498,
87-98[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Ashcroft, F. M.,
and Gribble, F. M.
(1998)
Trends Neurosci.
21,
288-294[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Schwanstecher, M.,
Steverding, C.,
Dorschner, H.,
Gross, I.,
Aguilar-Bryan, L.,
Schwanstecher, C.,
and Bryan, J.
(1998)
EMBO J.
17,
5529-5535[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Zerangue, N.,
Schwappach, B.,
Jan, Y. N.,
and Jan, L. Y.
(1999)
Neuron
22,
537-548[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Tusnády, G. E.,
Bakos, E.,
Váradi, A.,
and Sarkadi, B.
(1997)
FEBS Lett.
402,
1-3[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Aguilar-Bryan, L.,
Nichols, C. G.,
Wechsler, S. W.,
Clement, J. P., IV,
Boyd, A. E., III,
González, G.,
Herrera-Sosa, H.,
Nguy, K.,
Bryan, J.,
and Nelson, D. A.
(1995)
Science
268,
423-426[Abstract/Free Full Text]
|
| 15.
|
Nelson, D. A.,
Bryan, J.,
Wechsler, S.,
Clement, J. P., IV,
and Aguilar-Bryan, L.
(1996)
Biochemistry
35,
14793-14799[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Clement, J. P. I.,
Kunjilwar, K.,
González, G.,
Schwanstecher, M.,
Panten, U.,
Aguilar-Bryan, L.,
and Bryan, J.
(1997)
Neuron
18,
827-838[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Nichols, C. G.,
Shyng, S. L.,
Nestorowicz, A.,
Glaser, B.,
Clement, J. P., IV,
González, G.,
Aguilar-Bryan, L.,
Permutt, M. A.,
and Bryan, J.
(1996)
Science
272,
1785-1787[Abstract]
|
| 18.
|
Gribble, F. M.,
Tucker, S. J.,
Haug, T.,
and Ashcroft, F. M.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
7185-7190[Abstract/Free Full Text]
|
| 19.
|
Shyng, S.,
Ferrigni, T.,
and Nichols, C. G.
(1997)
J. Gen. Physiol.
110,
643-654[Abstract/Free Full Text]
|
| 20.
|
Gao, M.,
Yamazaki, M.,
Loe, D. W.,
Westlake, C. J.,
Grant, C. E.,
Cole, S. P. C.,
and Deeley, R. G.
(1998)
J. Biol. Chem.
273,
10733-10740[Abstract/Free Full Text]
|
| 21.
|
Blobel, G.,
and Dobberstein, B.
(1975)
J. Cell Biol.
67,
835-851[Abstract/Free Full Text]
|
| 22.
|
Skach, W. R.,
and Lingappa, V. R.
(1993)
in
Mechanisms of Intracellular Trafficking and Processing of Proproteins
(Loh, Y. P., ed)
, pp. 19-77, CRC Press, Boca Raton, FL
|
| 23.
|
Hartmann, E.,
Rapoport, T. A.,
and Lodish, H. F.
(1989)
Proc. Natl. Acad. Sci. U. S. A.
86,
5786-5790[Abstract/Free Full Text]
|
| 24.
|
Kyte, J.,
and Doolittle, R. F.
(1982)
J. Mol. Biol.
157,
105-132[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Tusnády, G. E.,
and Simon, I.
(1998)
J. Mol. Biol.
283,
489-506[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Sonnhammer, E. L.,
von Heijne, G.,
and Krogh, A.
(1998)
Intell. Syst. Mol. Biol.
6,
175-182
|
| 27.
|
Hirokawa, T.,
Boon-Chieng, S.,
and Mitaku, S.
(1998)
Bioinformatics
14,
378-379[Abstract/Free Full Text]
|
| 28.
|
Rost, B.,
Fariselli, P.,
and Casadio, R.
(1996)
Protein Sci.
5,
1704-1718[Abstract]
|
| 29.
|
von Heijne, G.
(1992)
J. Mol. Biol.
225,
487-494[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Rothman, R. E.,
Andrews, D. W.,
Calayag, M. C.,
and Lingappa, V. R.
(1988)
J. Biol. Chem.
263,
10470-10480[Abstract/Free Full Text]
|
| 31.
|
Chavez, R. A.,
and Hall, Z. W.
(1991)
J. Biol. Chem.
266,
15532-15538[Abstract/Free Full Text]
|
| 32.
|
Parks, G. D.,
and Lamb, R. A.
(1993)
J. Biol. Chem.
268,
19101-19109[Abstract/Free Full Text]
|
| 33.
|
Struhl, K.
(1991)
in
Current Protocols in Molecular Biology
(Ausubel, F. M.
, Brent, R.
, Kingston, R. E.
, Moore, D. D.
, Seidman, J. G.
, Smith, J. A.
, and Struhl, K., eds)
, pp. 10.17.1-10.17.5, John Wiley & Sons, Inc., New York
|
| 34.
|
Bennett, J. A.,
and Dingledine, R.
(1995)
Neuron
14,
373-384[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Bakos, É.,
Hegedüs, T.,
Holló, Z.,
Welker, E.,
Tusnády, G. E.,
Zaman, G. J. R.,
Flens, M. J.,
Váradi, A.,
and Sarkadi, B.
(1996)
J. Biol. Chem.
271,
12322-12326[Abstract/Free Full Text]
|
| 36.
|
Hipfner, D. R.,
Almquist, K. C.,
Leslie, E. M.,
Gerlach, J. H.,
Grant, C. E.,
Deeley, R. G.,
and Cole, S. P. C.
(1997)
J. Biol. Chem.
272,
23623-26330[Abstract/Free Full Text]
|
| 37.
|
Chang, X. B.,
Hou, Y. X.,
Jensen, T. J.,
and Riordan, J. R.
(1994)
J. Biol. Chem.
269,
18572-18575[Abstract/Free Full Text]
|
| 38.
|
Katz, F. N.,
Rothman, J. E.,
Lingappa, V. R.,
Blobel, G.,
and Lodish, H. F.
(1977)
Proc. Natl. Acad. Sci. U. S. A.
74,
3278-3282[Abstract/Free Full Text]
|
| 39.
|
Dunlop, J.,
Jones, P. C.,
and Finbow, M. E.
(1995)
EMBO J.
14,
3609-3616[Medline]
[Order article via Infotrieve]
|
| 40.
|
Kast, C.,
and Gros, P.
(1997)
J. Biol. Chem.
272,
26479-26487[Abstract/Free Full Text]
|
| 41.
|
Kast, C.,
and Gros, P.
(1998)
Biochemistry
37,
2305-2313[CrossRef][Medline]
[Order article via Infotrieve]
|
| 42.
|
Levy, D.
(1996)
Essays Biochem.
31,
49-60[Medline]
[Order article via Infotrieve]
|
| 43.
|
Zhang, J. T.
(1996)
Mol. Biol. Cell
7,
1709-1721[Abstract]
|
| 44.
|
Skach, W. R.,
Calayag, M. C.,
and Lingappa, V. R.
(1993)
J. Biol. Chem.
268,
6903-6908[Abstract/Free Full Text]
|
| 45.
|
Hegde, R. S.,
Mastrianni, J. A.,
Scott, M. R.,
DeFea, K. A.,
Tremblay, P.,
Torchia, M.,
DeArmond, S. J.,
Prusiner, S. B.,
and Lingappa, V. R.
(1998)
Science
279,
827-834[Abstract/Free Full Text]
|
| 46.
|
Stride, B. D.,
Valdimarsson, G.,
Gerlach, J. H.,
Wilson, G. M.,
Cole, S. P. C.,
and Deeley, R. G.
(1996)
Mol. Pharmacol.
49,
962-971[Abstract]
|
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
R. G. Deeley, C. Westlake, and S. P. C. Cole
Transmembrane Transport of Endo- and Xenobiotics by Mammalian ATP-Binding Cassette Multidrug Resistance Proteins.
Physiol Rev,
July 1, 2006;
86(3):
849 - 899.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Teramoto
Physiological roles of ATP-sensitive K+ channels in smooth muscle
J. Physiol.,
May 1, 2006;
572(3):
617 - 624.
[Abstract]
[Full Text]
[PDF]
|
 |
|